Current Outcome of Patients With Ureteral Stents for the Management of Malignant Ureteral Obstruction
|
|
- Randall Harper
- 6 years ago
- Views:
Transcription
1 Current Outcome of Patients With Ureteral Stents for the Management of Malignant Ureteral Obstruction Kouji Izumi,* Atsushi Mizokami, Yuji Maeda, Eitetsu Koh and Mikio Namiki From the Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan Abbreviations and Acronyms GIT gastrointestinal tract MUO malignant ureteral obstruction OS overall survival PCN percutaneous nephrostomy RUS retrograde ureteral stent placement SCr serum creatinine SFFS stent failure-free survival UU ureteral unit Submitted for publication June 7, * Correspondence: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa , Japan (telephone: ; FAX: ; azuizu2003@yahoo.co.jp). See Editorial on page 387. Purpose: We analyzed the prognostic factors associated with overall survival and predictive factors of stent failure in patients treated with an indwelling retrograde ureteral stent for malignant ureteral obstruction. Materials and Methods: Among 186 Japanese patients treated with an indwelling retrograde ureteral stent for ureteral obstruction from January 2005 to March 2010, 61 with malignant ureteral obstruction and 95 ureteral units were analyzed retrospectively. Results: Median survival was estimated at 228 days. Unfavorable prognostic factors of overall survival were no treatment after indwelling retrograde ureteral stent placement (p 0.023) and a serum creatinine before indwelling retrograde ureteral stent placement of 1.2 mg/dl or greater (p 0.016). Overall survival differed significantly among cancer groups (p 0.001) as did stent failure-free survival (p 0.011). Overall survival differed significantly among 3 risk groups divided according to the score calculated with regard to prognostic factors (p 0.001). Conclusions: Gynecologic cancer was a significant favorable predictor of stent failure-free survival. Patients treated with an indwelling retrograde ureteral stent for malignant ureteral obstruction were divided into 3 groups, which showed significant differences in overall survival. This risk classification may help urologists predict survival time. Key Words: stents, ureteral obstruction, neoplasm metastasis THE appearance of ureteral obstruction caused by metastasis or invasion of malignancy is generally regarded as a sign of poor prognosis. The cause of malignant MUO may be invasion of the ureter by cervical, bladder, prostate or colorectal cancer, extrinsic compression by a retroperitoneal primary lesion, metastatic neoplasia from distant primary lesion or peritonitis carcinomatosa of GIT primary lesion. 1 RUS does not usually lead to major complications, is less invasive than PCN and is better tolerated, suggesting that it may be more advantageous than PCN especially in view of the limited life expectancy of patients with advanced malignancies. 2,3 However, stent failure is a problem encountered frequently by urologists. Furthermore, the frequency of the primary site of malignancy differs considerably among countries. These differences in primary site may impact clinical outcomes such as survival time. Accordingly median survival of patients with MUO was reported over a wide range from 3.7 to 15.3 months. 2,4 In addition, the recent development of chemotherapeutic agents or emergence of molecular targeting therapies improved the OS /11/ /0 Vol. 185, , February 2011 THE JOURNAL OF UROLOGY Printed in U.S.A by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC. DOI: /j.juro
2 URETERAL STENT FOR MALIGNANT URETERAL OBSTRUCTION 557 of patients with cancer. However, there have been only a few reports of data from such patients in recent years. In this study we analyzed the prognostic factors in recent cases of RUS for MUO and predictive factors of stent failure. To aid urologists in predicting patient survival we defined risk classification for patient prognosis. MATERIALS AND METHODS Patients This retrospective analysis followed the Helsinki Declaration. Among 186 Japanese patients who underwent RUS under x-ray guidance for ureteral obstruction at Kanazawa University Hospital between January 2005 and March 2010, 61 patients with 95 UUs for MUO with hydronephrosis were extracted. The date of the initial RUS attempt was used as the start of observation. OS was measured from the start of observation to death from any cause. SFFS was measured from the start of observation to stent failure. We defined stent failure as UUs that required an alternative form of urinary diversion. The obstruction level was defined as the upper, middle or lower ureter as determined by the location above, over or below the sacroiliac joint. In cases in which the obstruction levels were different between bilateral ureters, the more severely obstructed side was selected. Multi-length ureteral stents of 4.8 or 6Fr (Contour ) were used. The interval between stent changes was initially planned at 3 months. RUS related major complications such as severe bleeding which needs transfusion, stent migration and uncontrollable sepsis were assessed. Statistical Analysis Statistical analyses were performed using commercially available software (PRISM and SPSS version 17.0). The crude probability of survival was estimated using the Kaplan-Meier method. Univariate analysis of differences among patient groups was performed with the log rank test. Multivariate analysis to identify independent prognostic factors was performed with Cox proportional hazards regression and the stepwise backward procedure, with statistical significance defined as p RESULTS Table 1. Patient characteristics Median pt age (range) 64 (27 89) No. gender (%): M 19 (31) F 42 (69) No. side (%): Bilat 25 (41) Lt 16 (26) Rt 20 (33) No. gynecologic Ca group (%): 21 (34) Cervical 13 (21) Endometrial 1 (2) Ovarian 7 (11) No. upper gastrointestinal Ca group (%): 13 (21) Gastric 12 (20) Esophageal 1 (2) No. lower gastrointestinal Ca group (%): 10 (16) Rectal 6 (10) Colon 4 (7) No. urological Ca group (%): 10 (16) Retroperitoneal tumor 3 (5) Prostate 2 (3) Bladder 2 (3) Ureteral 2 (3) Adrenal 1 (2) No. other Ca group (%): 7 (11) Lung 2 (3) Pancreas 2 (3) Breast 1 (2) Liver 1 (2) Malignant melanoma 1 (2) Median (range) SCr (mg/dl): 1.11 ( ) No. 1.2 or greater (%) 24 (39) No. less than 1.2 (%) 29 (48) No. unknown (%) 8 (13) No. obstruction level (%): Upper middle ureter 34 (56) Lower ureter 22 (36) Unknown 5 (8) No. no treatment after retrograde stenting (%) 22 (36) No. treatment after retrograde stenting (%): 39 (64) Chemotherapy 26 (43) Radiation 3 (5) Chemoradiation 5 (8) Immunotherapy 1 (2) Hormonal therapy 1 (2) Surgery 3 (5) Patient Population Patient characteristics are shown in table 1. In a total of 61 patients with 95 UUs in which RUS was attempted, the stent failed to indwell in 13 patients (21.3%) and 17 UUs (17.9%). The numbers of patients with bilateral and unilateral RUS failure were 4 (8 UUs) and 9 (9 UUs), respectively. The reasons for RUS failure were severe ureteral stricture (9 UUs), undetectable orifice (3 UUs), severe pain (2 UUs), kink of the ureter, deviation of the orifice and urethral stricture (each 1 UU). For prompt rescue of initial RUS failure 2 patients underwent PCN on the same day. RUS at 7 days and 6 months, and PCN at 8 months after the date of initial RUS failure were performed in 1 patient each. The data of SCr before RUS in 8 patients and 12 UUs, and of obstruction level in 5 patients and 5 UUs were not available, and were omitted from analysis. Nadir SCr after successful RUS of 1.2 mg/dl or greater and less than 1.2 mg/dl were available in 8 and 38 patients, respectively. A total of 78 initially successful UUs were analyzed statistically and the characteristics of these 78 UUs are shown in table 2. Nadir SCr after successful RUS of 1.2 mg/dl or greater and less than 1.2 mg/dl were available in 12 and 54 UUs, respectively. There were no RUS related major complications.
3 558 URETERAL STENT FOR MALIGNANT URETERAL OBSTRUCTION Table 2. Characteristics of ureteral units No. gender (%): M 24 (31) F 54 (69) No. side (%): L 38 (49) R 40 (51) No. gynecologic Ca group (%): 28 (36) Cervical 20 (26) Endometrial 1 (1) Ovarian 7 (9) No. upper gastrointestinal Ca group (%): 20 (26) Gastric 19 (24) Esophageal 1 (1) No. lower gastrointestinal Ca group (%): 9 (12) Rectal 4 (5) Colon 5 (6) No. urological Ca group (%): 13 (17) Retroperitoneal tumor 4 (5) Prostate 4 (5) Bladder 2 (3) Ureteral 2 (3) Adrenal 1 (1) No. other Ca group (%): 8 (10) Lung 2 (3) Pancreas 1 (1) Breast 2 (3) Liver 2 (2) Malignant melanoma 1 (2) Median (range) SCr (mg/dl): 1.10 ( ) No. 1.2 or greater (%) 30 (38) No. less than 1.2 (%) 36 (46) No. unknown (%) 12 (15) No. obstruction level (%): Upper middle ureter 50 (64) Lower ureter 23 (29) Unknown 5 (6) No. no treatment after retrograde stenting (%) 33 (42) No. treatment after retrograde stenting (%): 45 (58) Chemotherapy 30 (43) Radiation 4 (5) Chemoradiation 5 (6) Immunotherapy 1 (1) Hormonal therapy 2 (3) Surgery 3 (4) No. Fr stent diameter (%): (50) 6 36 (46) Unknown 3 (4) Prognostic Factors for OS Median survival was estimated at 228 days. The effects of each prognostic factor on OS were examined with univariate analysis. Unfavorable prognostic factors for OS were male gender (p 0.031, HR 2.336, 95% CI ), no treatment after RUS (p 0.023, HR % CI ) and SCr before RUS of 1.2 mg/dl or greater (p 0.016, HR 2.426, 95% CI ). OS also differed significantly among cancer groups (p 0.001), and median OS of gynecologic cancer, urological cancer, lower GIT cancer, upper GIT cancer and cancer of other primary sites was 510, 403, 252, 148 and 53 days, respectively. Age 64 years old or older (p 0.202, HR 1.536, 95% CI ), nadir SCr after successful RUS of 1.2 mg/dl or greater (p 0.087, HR 3.208, 95% CI ) and initial failure of RUS (p 0.504, HR 1.290, 95% CI ) were not significant factors for OS. Attempted RUS into bilateral ureters (p 0.079, HR 1.817, 95% CI ), and upper and middle ureteral obstruction (p 0.076, HR 1.815, 95% CI ) were marginally significant predictors of unfavorable prognosis. On multivariate analysis SCr before RUS of 1.2 mg/dl or greater (p 0.011, HR 2.501, 95% CI ) and no treatment after RUS (p 0.028, HR 2.222, 95% CI ) remained significant predictors of unfavorable prognosis. Type of cancer remained a marginally significant prognostic factor (p 0.050, HR 1.303, 95% CI ) (table 3). Predictors of SFFS Median stent placement period for 78 UUs was 89.5 days and 17 UUs (21.8%) had stent failure in the followup period. The numbers of UUs undergoing PCN and metallic ureteral stent placement for stent failure were 11 and 5, respectively. In addition, PCN and metallic ureteral stent placement were performed in 1 UU for a persistently increasing SCr despite unilateral urinary diversion. The frequency of stent change was not clear in 9 of 78 UUs because they were followed elsewhere. The stents were not changed before stent failure or death in 41 of the remaining 69 UUs. The largest number of stent changes in a single patient was 16 in 1,484 days in a patient with cervical cancer. The average interval between stent changes was days. The effects of each prognostic factor on SFFS were examined by univariate analysis. Male gender was an unfavorable Table 3. Multivariate analysis of variables and median survival time No. Pts Median Days Survival HR (95% CI) p Value Gender: ( ) M F Ca group: ( ) Gynecologic Upper gastrointestinal Lower gastrointestinal Urological Other 7 53 SCr (mg/dl): ( ) or Greater Less than Treatment after stenting: ( ) No Yes
4 URETERAL STENT FOR MALIGNANT URETERAL OBSTRUCTION 559 predictor of SFFS (p 0.015, HR 5.454, 95% CI ). SFFS also differed significantly among cancer groups (p 0.011), and median SFFS of urological cancer, lower GIT cancer, upper GIT cancer and cancer of other primary sites was 588, 255, 512 and 62 days, respectively. Median SFFS of gynecologic cancer was not reached. Age 64 years old or older (p 0.801, HR 1.139, 95% CI ), SCr before RUS of 1.2 mg/dl or greater (p 0.597, HR 1.419, 95% CI ), nadir SCr after successful RUS of 1.2 mg/dl or greater (p 0.124, HR 6.773, 95% CI ), upper and middle ureteral obstruction (p 0.105, HR 2.485, 95% CI ), stent diameter of 4.8Fr (p 0.060, HR 2.606, 95% CI ), no treatment after RUS (p 0.145, HR 2.100, 95% CI ) and left side (p 0.457, HR 1.453, 95% CI ) were not significant factors for SFFS. On multivariate analysis type of cancer remained a significant predictor of SFFS (p 0.011, HR 1.626, 95% CI ) (table 4). Gynecologic cancer was an especially significant favorable predictor of SFFS (fig. 1). Figure 1. Kaplan-Meier analysis of SFFS in cases of gynecologic and other cancers (p 0.011). Gynecologic cancer was especially significant favorable predictor of SFFS. Risk Classification for OS A total of 53 patients were divided into 3 risk groups according to the scores calculated with regard to 4 prognostic factors. As SCr before RUS of 1.2 mg/dl or greater and no treatment after RUS were significant predictors of unfavorable prognosis, patients who had these factors were given a score of 2 points. Type of cancer was also a significant predictor of prognosis, and cancer groups were divided in 3 categories of gynecologic cancer (category A), urological and lower GIT cancer (category B), and upper GIT cancer and other cancer (category C). Patients in categories B and C were given scores of 1 and 2 points, respectively. The patients in whom RUS was attempted into the bilateral ureters were given a score of 1 point because this was a marginally significant predictor of unfavorable prognosis. However, obstruction level was excluded from prognostic factors because primary cancer site was thought to be strongly connected with obstruction level. Therefore, all patients were given a score from 0 to 7 in accordance with 4 prognostic factors. Patients with scores of 0 to 2 were assigned to the good prognosis group, those with scores of 3 or 4 were assigned to the intermediate prognosis group and those with scores of 5 to 7 were assigned to the poor prognosis group. According to this risk classification the numbers of patients in good, intermediate and poor prognosis groups were 20, 20 and 13, respectively, and OS differed significantly among these 3 groups (p 0.001, fig. 2). Median survival times of good, intermediate and poor prognosis groups were 403, 252 and 51 days, respectively. DISCUSSION Experience with ureteral stents was first reported in 1978 and stents were subsequently used for patients with malignancies that were causing external compression of the ureter. 1,5 Although benign, intrinsic ureteral obstruction such as stone Table 4. Multivariate analysis of variables and median SFFS time No. Pts Median (Days) SFFS HR (95% CI) p Value Gender: ( ) M F Ca group: ( ) Gynecologic 28 Undefined Upper gastrointestinal Lower gastrointestinal Urological Other 8 62 Figure 2. Kaplan-Meier analysis of OS in each risk group. OS differed significantly among 3 groups (p 0.001).
5 560 URETERAL STENT FOR MALIGNANT URETERAL OBSTRUCTION disease, ureteral stricture or ureteropelvic junction obstruction is usually successfully managed in the long term by RUS, the incidence of stent failure is significantly higher in cases of MUO. 1 In the present study the success rate of initial RUS was 79%, which was consistent with the rates of 72% to 92% in previous reports of MUO. 2,6 However, the rate of late stent failure was reported with a wide range from 16% to 53%. 4,7 10 In a study of 103 advanced malignancies 51% of patients required secondary PCN 4 and in a cohort of 39 UUs with MUO 43% of UUs were reobstructed. 7 In addition, in 15-year experience of the management of extrinsic ureteral obstruction, 44% of patients with MUO had stent failure. 8 In contrast, in 2 studies published in 2007 only 16% of patients with nonurological MUO and 21.6% of those with MUO, including urological malignancy, had stent failure. 9,10 In the present study 21.8% of UUs had stent failure and this result was equivalent to those of recent studies. Although the differences in rate of stent failure among previous studies were explained as the result of improvements in stent design and biocompatibility, 8,9 these studies could not be directly compared with each other because of obvious differences in patient background, sample size and etiology of malignancy. Accordingly different factors were considered predictors of SFFS or OS. Factors reported as predictors of stent failure were baseline SCr, no treatment after RUS, gross tumor invasion noted at cystoscopy, degree of hydronephrosis and male gender. 8,9,11,12 Type of cancer was a significant predictor of SFFS in the present study and gynecologic cancer was an especially good predictor of better SFFS. To our knowledge this is the first report that type of cancer is a significant predictor of SFFS. However, the results should be interpreted carefully because the patient backgrounds differed considerably among studies. The OS of patients with MUO was also examined previously and median survival times were reported over a wide range. Median survival in the present study was 228 days (7.6 months), and SCr before RUS of 1.2 mg/dl or greater, no treatment after RUS and cancer group (especially nongynecologic cancer) were significant or marginally significant factors for OS. The shortest median survival time previously reported was 3.7 months in a study in which 57% of patients had urological cancer. 4 In contrast, a median survival of 15.3 months was reported in another study of 28 patients with MUO. However, more than half of the patients in the study had gynecologic cancer. 2 Most previous studies included only a few patients with gastric cancer. Although the estimated rate of gastric cancer is only 1.4% of newly diagnosed cancers in the United States, 13 it has a highly malignant nature and is the second leading cause of cancer death in the world. 14 A study including gastric cancer (33% of patients) indicated median survival was 8.6 months, 9 which was equivalent to the present study. This previous study concluded that patients with a low performance status, upper ureteral obstruction, no chemotherapy after RUS and GIT cancer had a short survival time. 9 Wong et al proposed risk factors for inferior OS in patients with intervention for MUO including presence of metastasis, prior therapy, diagnosis of MUO in previously established malignancy and high SCr. 15 Although patients with 3 or 4 of these risk factors were associated with poor survival, only 25 of 102 underwent RUS. The present study may be reasonable for examination of OS because it had a well balanced patient background with regard to type of cancer. In our risk classification patients who underwent RUS for MUO were divided into 3 groups which differed significantly in OS. This classification may be applied universally and help urologists predict survival time. The present study had a number of limitations. Small sample size may have prevented determination of precise statistical significance. Several factors previously reported as significant factors for OS or SFFS were not considered prognostic variables because they were not clear in some patients. All patients were Japanese so the distribution of cancer may differ in patients from other ethnic backgrounds. Hematological malignancies such as lymphoma were not included in the present study. In addition, SCr before RUS was relatively low, and median survival may be lengthened by lead time bias. Finally, our risk classification should be confirmed by prospective validation study before it can be used routinely in clinical settings. CONCLUSIONS Gynecologic cancer was a favorable predictor of SFFS. SCr before RUS of 1.2 mg/dl or greater and no treatment after RUS were significant predictors of unfavorable prognosis, and type of cancer was a marginally significant predictor of OS. The risk classification calculated using these 3 predictive factors and attempted RUS into bilateral ureters could concisely assign patients into 3 groups with significantly different OS. This risk classification may help urologists predict survival.
6 URETERAL STENT FOR MALIGNANT URETERAL OBSTRUCTION 561 REFERENCES 1. Sountoulides P, Pardalidis N and Sofikitis N: Endourologic management of malignant ureteral obstruction: indications, results, and quality-of-life issues. J Endourol 2010; 24: Rosenberg BH, Bianco FJ Jr, Wood DP Jr et al: Stent-change therapy in advanced malignancies with ureteral obstruction. J Endourol 2005; 19: Rosevear HM, Kim SP, Wenzler DL et al: Retrograde ureteral stents for extrinsic ureteral obstruction: nine years experience at University of Michigan. Urology 2007; 70: Shekarriz B, Shekarriz H, Upadhyay J et al: Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer 1999; 85: Finney RP: Experience with new double J ureteral catheter stent. J Urol 1978; 120: Donat SM and Russo P: Ureteral decompression in advanced nonurologic malignancies. Ann Surg Oncol 1996; 3: Yossepowitch O, Lifshitz DA, Dekel Y et al: Predicting the success of retrograde stenting for managing ureteral obstruction. J Urol 2001; 166: Chung SY, Stein RJ, Landsittel D et al: 15-Year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol 2004; 172: Jeong IG, Han KS, Joung JY et al: The outcome with ureteric stents for managing non-urological malignant ureteric obstruction. BJU Int 2007; 100: Kanou T, Fujiyama C, Nishimura K et al: Management of extrinsic malignant ureteral obstruction with urinary diversion. Int J Urol 2007; 14: Ganatra AM and Loughlin KR: The management of malignant ureteral obstruction treated with ureteral stents. J Urol 2005; 174: Wenzler DL, Kim SP, Rosevear HM et al: Success of ureteral stents for intrinsic ureteral obstruction. J Endourol 2008; 22: Jemal A, Siegel R, Ward E et al: Cancer statistics, CA Cancer J Clin 2009; 59: Parkin DM, Bray F, Ferlay J et al: Global cancer statistics, CA Cancer J Clin 2005; 55: Wong LM, Cleeve LK, Milner AD et al: Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol 2007; 178: 178.
Predicting the failure of retrograde ureteral stent insertion for managing malignant ureteral obstruction in outpatients
ONCOLOGY LETTERS 11: 879-883, 2016 Predicting the failure of retrograde ureteral stent insertion for managing malignant ureteral obstruction in outpatients JIN YOU WANG 1,2*, HAI LIANG ZHANG 1,2*, YAO
More informationRenal function is associated with prognosis in stent-change therapy for malignant ureteral obstruction
Original Article - Endourology/Urolithiasis pissn 2466-0493 eissn 2466-054X Renal function is associated with prognosis in stent-change therapy for malignant ureteral obstruction Ji Hyung Yoon, Sejun Park,
More informationObjectives: To analyze various factors predicting success of retrograde ureteric stenting in managing patients with ureteric obstruction.
ISPUB.COM The Internet Journal of Urology Volume 14 Number 1 Factors Predicting Success Rate Of Retrograde Ureteric Stenting In Managing Patients With Ureteric Obstruction- Our Experiences In A South Indian
More informationBilateral Hydronephrosis in Adults: To Do or Not To Do Percutaneous Nephrostomy
Bilateral Hydronephrosis in Adults: To Do or Not To Do Percutaneous Nephrostomy Poster No.: C-0802 Congress: ECR 2014 Type: Educational Exhibit Authors: S.-H. You, D. J. Sung, N. Y. Han, B. J. Park, M.
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationManual Replacement of Double J Stent Without Fluoroscopy. Osman Kose, Sacit Nuri Gorgel, Sait Ozbir, Sekan Yenigurbuz, Cengiz Kara
Int Surg 2015;100:381 385 DOI: 10.9738/INTSURG-D-13-00248.1 Manual Replacement of Double J Stent Without Fluoroscopy (Double j stent replacement) Osman Kose, Sacit Nuri Gorgel, Sait Ozbir, Sekan Yenigurbuz,
More informationObstructive Uropathy. PATHOPHYSIOLOGIC CHANGES UUO vs BUO. Arry Rodjani Urology Department Ciptomangunkusumo Hospital Jakarta
Obstructive Uropathy PATHOPHYSIOLOGIC CHANGES UUO vs BUO Arry Rodjani Urology Department Ciptomangunkusumo Hospital Jakarta INTRODUCTION Obstructive uropathy refers to the functional or anatomic obstruction
More informationMedical technologies guidance Published: 1 February 2018 nice.org.uk/guidance/mtg35
Memokath-051 stent for ureteric obstruction Medical technologies guidance Published: 1 February 2018 nice.org.uk/guidance/mtg35 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationThe role of procalcitonin in differentiation between bacterial infection and neoplastic fever
1 Short Communications The role of procalcitonin in differentiation between bacterial infection and neoplastic fever in patients with advanced urological cancer Hiroshi Yaegashi, Kouji Izumi*, Yasuhide
More informationHydronephrosis. What is hydronephrosis?
What is hydronephrosis? Hydronephrosis Hydronephrosis describes the situation where the urine collecting system of the kidney is dilated. This may be a normal variant or it may be due to an underlying
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationObstructive Uropathy in Gynecologic Malignancy and Value of Percutaneous Nephrostomy
Original Article GCSMC J Med Sci Vol (IV) No (II) July-December 2015 Obstructive Uropathy in Gynecologic Malignancy and Value of Percutaneous Nephrostomy Pariseema S. Dave *, Bijal M. Patel**, Himanshu
More informationThe Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma
Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationC. Patel 1*, D. Loughran 1, R. Jones 1, M. Abdulmajed 1 and I. Shergill 1,2
Patel et al. BMC Urology (2017) 17:16 DOI 10.1186/s12894-017-0204-8 RESEARCH ARTICLE The resonance metallic ureteric stent in the treatment of chronic ureteric obstruction: a safety and efficacy analysis
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationCLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION
Donald L. Renfrew, MD Radiology Associates of the Fox Valley, 333 N. Commercial Street, Suite 100, Neenah, WI 54956 1/22/2011 Radiology Quiz of the Week # 4 Page 1 CLINICAL PRESENTATION AND RADIOLOGY QUIZ
More informationThe Association Between The Prognosis Of Ureteral Cancer And Natural Constriction By The Common Iliac Arteriovenous Crossing
ISPUB.COM The Internet Journal of Urology Volume 15 Number 1 The Association Between The Prognosis Of Ureteral Cancer And Natural Constriction By The Common Iliac Arteriovenous Crossing K Takahara, S Tobu,
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationeuropean urology 50 (2006)
european urology 50 (2006) 1073 1078 available at www.sciencedirect.com journal homepage: www.europeanurology.com Reconstructive Urology Nephrovesical Subcutaneous Ureteric Bypass: Long-term Results in
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationCitation International journal of urology (2. Right which has been published in final f
Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationA prediction model of survival for patients with bone metastasis from uterine corpus cancer
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(11) 973 978 doi: 10.1093/jjco/hyw120 Advance Access Publication Date: 21 September 2016 Original Article Original
More informationUreteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor
Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor Scott G. Hubosky, MD The Demetrius H. Bagley Jr., MD Associate Professor of Urology Director of Endourology Vice Chair
More informationMultiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy
Brazilian Journal of Medical and Biological Research (2007) 40: 979-984 Predictive factors after radical cystectomy ISSN 0100-879X 979 Multiple factor analysis of metachronous upper urinary tract transitional
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationTreatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer Nobukazu Fuwa 1, Akinori Takada 2 and Takahiro Kato 3 1;Departments of Radiology, Hyogo Ion Beam Medical
More informationShould we still be performing IHC on all sentinel nodes?
Miami Breast Cancer Conference 31 st Annual Conference March 8, 2014 Should we still be performing IHC on all sentinel nodes? Donald L. Weaver, MD Professor of Pathology University of Vermont USA Miami
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationPelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer
Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer Esten S. Nakken MD PhD Division of Cancer Medicine Oslo University Hospital
More informationClinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
Douglas et al. BMC Cancer 2012, 12:425 RESEARCH ARTICLE Open Access A new score predicting the survival of patients with spinal cord compression from myeloma Sarah Douglas 1, Steven E Schild 2 and Dirk
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationNephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer
The British Journal of Radiology, 82 (2009), 571 576 Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer 1 J NARICULAM, MBBS, MRCS, 2 D G MURPHY, MBBS, MD,
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationColonic stenting anno 2014
Jeanin E. van Hooft, MD, PhD Gastroenterologist Academic Medical Centre Dept. of Gastroenterology and Hepatology Amsterdam, Netherlands Annual meeting of Colonic Stent Safe Procedure Research Group May
More informationRadical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors
ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau
More informationYASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI
Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI
More informationPrognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy
Prognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy 2016.04.08 KCCH 김문홍 DM and prediabetes in cancer Negative impact on
More informationLife Science Journal 2014;11(7)
Life Science Journal 4;(7) http://www.lifesciencesite.com Impact of primary tumor resection on response and survival in metastatic breast cancer patients Enas. A. Elkhouly¹, Eman. A. Tawfik ¹, Alaa. A.
More informationEvaluation of prognostic scoring systems for bone metastases using single center data
MOLECULAR AND CLINICAL ONCOLOGY 3: 1361-1370, 2015 Evaluation of prognostic scoring systems for bone metastases using single center data HIROFUMI SHIMADA 1, TAKAO SETOGUCHI 2, SHUNSUKE NAKAMURA 1, MASAHIRO
More informationA comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients
ONCOLOGY LETTERS 14: 299-305, 2017 A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients KOICHI SHOJI 1, JUN TEISHIMA 1, TETSUTARO
More informationObstructive Nephropathy
Obstructive Nephropathy Liza A. Lucero RN, FNP-C, MSN Renal Medicine Associates Conflicts No conflict of interests Obstructive Nephropathy Objectives Definition of Obstructive Nephropathy Causes Clinical
More informationDoes the Size of Ureteral Stent Impact Urinary Symptoms and Quality of Life? A Prospective Randomized Study
European Urology European Urology 48 (2005) 673 678 Endourology Does the Size of Ureteral Stent Impact Urinary Symptoms and Quality of Life? A Prospective Randomized Study Rocco Damiano a, *, Riccardo
More informationForgotten JJ stent: A rare case report
Ped Urol Case Rep 2015; 2(2):6-10 DOI: 10.14534/PUCR.201529390 PUCR Ped Urol Case Rep PEDIATRIC UROLOGY CASE REPORTS ISSN: 2148 2969 Journal homepage: http://www.pediatricurologycasereports.com Forgotten
More informationSurgical Management of Pancreatic Cancer
I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationBladder Case # 1. Principal Diagnosis: Bladder Tumor, Suspect Transitional Cell Carcinoma. Secondary Diagnoses: 1. Hypertension. 2. Hyperlipidemia.
DISCHARGE SUMMARY Bladder Case # 1 Date: 04/22/2010 Principal Diagnosis: Bladder Tumor, Suspect Transitional Cell Carcinoma. Secondary Diagnoses: 1. Hypertension. 2. Hyperlipidemia. Hospital Course: Mr.
More informationLog odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection
Original Article Log odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection Mingjian Yang 1,2, Hongdian Zhang 1,2, Zhao Ma 1,2, Lei Gong 1,2, Chuangui Chen
More information1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC.
ISRN Urology Volume 2013, Article ID 405064, 5 pages http://dx.doi.org/10.1155/2013/405064 Research Article Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in
More informationJaspreet S. Sandhu,*,, Geoffrey T. Gotto,*, Luis A. Herran, Peter T. Scardino, James A. Eastham and Farhang Rabbani
Age, Obesity, Medical Comorbidities and Surgical Technique are Predictive of Symptomatic Anastomotic Strictures After Contemporary Radical Prostatectomy Jaspreet S. Sandhu,*,, Geoffrey T. Gotto,*, Luis
More informationDouglas G. Adler MD. ACG Regional Postgraduate Course - Nashville, TN Copyright 2013 American College of Gastroenterology
Enteral Stents 2013: State of the Art Douglas G. Adler MD Associate Professor of Medicine Director of Therapeutic Endoscopy University of Utah School of Medicine Huntsman Cancer Center Esophageal Stents
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationCircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer
European Review for Medical and Pharmacological Sciences 2018; 22: 3713-3718 CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer N. LIU 1, J. ZHANG 1, L.-Y. ZHANG 1, L.
More informationCON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer
CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationCase Based Urology Learning Program
Case Based Urology Learning Program Resident s Corner: UROLOGY Case Number 19 CBULP 2011 044 Case Based Urology Learning Program Editor: Associate Editors: Manager: Case Contributors: Steven C. Campbell,
More informationEarly-Stage Clinical Experiences of Holmium Laser Enucleation of the Prostate (HoLEP)
JRural Med 2007 ; 2 : 93 97 Original article Early-Stage Clinical Experiences of Holmium Laser Enucleation of the Prostate (HoLEP) Shuzo Hamamoto 1,TakehikoOkamura 1,HideyukiKamisawa 1,KentaroMizuno 1,
More information90% of bladder tumours are transitional cell carcinoma (TCC), the remaining 10% of cases are squamous cell carcinoma, adenocarcinoma and sarcoma.
The Role of the Interventional Radiologist in Management of Post-Radical Cystectomy Ureteral Obstruction : A Case Review of Retrograde Transileal Conduit Ureteric Stents. Poster No.: C-2288 Congress: ECR
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationRESEARCH ARTICLE. Factors Affecting Survival in Patients with Colorectal Cancer in Shiraz, Iran
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.1.159 RESEARCH ARTICLE Factors Affecting Survival in Patients with Colorectal Cancer in Shiraz, Iran Mohammad Zare-Bandamiri 1, Narges Khanjani 2 *, Yunes Jahani
More informationLong-Term Complications of Conduit Urinary Diversion
Long-Term Complications of Conduit Urinary Diversion Mark S. Shimko,* Matthew K. Tollefson, Eric C. Umbreit, Sara A. Farmer, Michael L. Blute and Igor Frank From the Department of Urology (MSS, MKT, ECU,
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationLymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationA Case Report Hydronephrosis and Hydrodureter due to Ureteral Deep Infiltrating Endometriosis mimic Ureteral Stricture Suryamanggala SI 1, Satria ML 2
A Case Report Hydronephrosis and Hydrodureter due to Ureteral Deep Infiltrating Endometriosis mimic Ureteral Stricture Suryamanggala SI 1, Satria ML 2 1 Departement of Obstetric and Gynecology Faculty
More informationChapter 3. Neoplasms. Copyright 2015 Cengage Learning.
Chapter 3 Neoplasms Terminology Related to Neoplasms and Tumors Neoplasm New growth Tumor Swelling or neoplasm Leukemia Malignant disease of bone marrow Hematoma Bruise or contusion Classification of Neoplasms
More informationLower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance
Original Article Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance Dedrick Kok Hong Chan 1,2, Ker-Kan Tan 1,2 1 Division of Colorectal Surgery, University
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationCase Presentation - Pediatric Endourology
Case Presentation - Pediatric Endourology PA N E L : E U G ENE M I N EV I C H, U S A J O NAT H A N G L A S S, UK R OY M O R AG, I S R A E L YO R A M M O R, I S R A E L P I N C H AS L I V N E, I S R A E
More informationRadical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients
Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported
More informationImpact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery
Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation
More informationSignificance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma
ORIGINAL STUDY Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma Jeong-Yeol Park, MD, PhD, Dae-Yeon Kim, MD, PhD, Dae-Shik Suh, MD, PhD, Jong-Hyeok Kim, MD, PhD, Yong-Man
More informationUreteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes
ORIGINAL ARTICLE Vol. 43 (x): 2017 August 8.[Ahead of print] doi: 10.1590/S1677-5538.IBJU.2017.0218 Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes Muammer
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationSurvival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationLOWER POLE STONE DR.NOOR ASHANI MD YUSOFF DEPT. OF UROLOGY HOSP.KUALA LUMPUR
DR.NOOR ASHANI MD YUSOFF DEPT. OF UROLOGY HOSP.KUALA LUMPUR ! The appropriate treatment of lower pole calculi is controversial:! Shock wave lithotripsy! Retrograde ureteroscopy! Percutaneous lithotripsy
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More information